McKesson stock gains after Q2 growth and higher fiscal EPS view

Published on 11/07/2026 at 11:26 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

McKesson stock enters the second half after stronger fiscal second-quarter results. Management raised its adjusted EPS outlook for fiscal 2027.

McKesson enters second half stronger

Fiscal second-quarter revenue rose 8 percent to 111.0 billion US dollars.
Adjusted earnings per diluted share increased 18 percent to 11.68 US dollars.
Management raised fiscal 2027 adjusted EPS guidance to 45.60 to 46.40 US dollars.
Morgan Stanley raised its McKesson price target to 1,260 US dollars.

McKesson, US58155Q1031, Illustration mit AI erstellt.

McKesson reported stronger fiscal second-quarter results on Wednesday, November 4, and raised its full-year adjusted earnings outlook. The company said consolidated revenue increased 8 percent year over year to 111.0 billion US dollars, while adjusted earnings per diluted share rose 18 percent to 11.68 US dollars.

According to McKesson, growth came from North American Pharmaceutical, Oncology and Multispecialty, and Prescription Technology Solutions. Operating momentum and a lower share count supported the adjusted earnings increase.

Higher outlook sets second-half focus

McKesson raised its fiscal 2027 adjusted EPS range to 45.60 to 46.40 US dollars from 44.20 to 45.00 US dollars previously. The company said the new range implies 17 percent to 19 percent growth from the prior fiscal year. Excluding the impact of the Norway divestiture and prior gains in The US Oncology Network, management indicated growth of 19 percent to 21 percent.

The company expects fiscal 2027 revenue growth of 6 percent to 10 percent and operating profit growth of 12 percent to 16 percent. North American Pharmaceutical remains a key operating focus, with full-year operating profit growth projected at 14 percent to 18 percent.

Analyst target adds another signal

On Thursday, November 5, Morgan Stanley raised its McKesson price target to 1,260 US dollars from 1,207 US dollars and maintained an Overweight rating, according to Markets Insider. The change followed the quarterly update and gives investors a separate analyst reference point for the second half.

McKesson stock traded at 952.10 euros on Lang & Schwarz at 11:24 CET on Saturday, November 7, 2026.

Investors can follow the real-time quote of McKesson stock for the latest trading indication.